Lesley Fallowfield

1986–2025 年に発表

149
論文数
42,048
被引用数
101
h 指数
146
i10 指数

被引用数

Lesley Fallowfield の年別被引用数1971 年: 被引用 1 件1974 年: 被引用 2 件1981 年: 被引用 1 件1988 年: 被引用 3 件1989 年: 被引用 7 件1990 年: 被引用 8 件1991 年: 被引用 10 件1992 年: 被引用 13 件1993 年: 被引用 14 件1994 年: 被引用 18 件1995 年: 被引用 35 件1996 年: 被引用 27 件1997 年: 被引用 44 件1998 年: 被引用 52 件1999 年: 被引用 123 件2000 年: 被引用 119 件2001 年: 被引用 123 件2002 年: 被引用 135 件2003 年: 被引用 165 件2004 年: 被引用 177 件2005 年: 被引用 284 件2006 年: 被引用 250 件2007 年: 被引用 314 件2008 年: 被引用 358 件2009 年: 被引用 292 件2010 年: 被引用 280 件2011 年: 被引用 262 件2012 年: 被引用 259 件2013 年: 被引用 243 件2014 年: 被引用 244 件2015 年: 被引用 244 件2016 年: 被引用 258 件2017 年: 被引用 276 件2018 年: 被引用 229 件2019 年: 被引用 1,032 件2020 年: 被引用 1,189 件2021 年: 被引用 1,152 件2022 年: 被引用 826 件2023 年: 被引用 617 件2024 年: 被引用 1,037 件2025 年: 被引用 346 件2026 年: 被引用 10 件1972〜1973 年は被引用が無いため表示していません1975〜1980 年は被引用が無いため表示していません1982〜1987 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,039 件、この内訳の 21.8%イギリス: 引用元論文 1,547 件、この内訳の 11.1%中国: 引用元論文 798 件、この内訳の 5.7%イタリア: 引用元論文 749 件、この内訳の 5.4%ドイツ: 引用元論文 666 件、この内訳の 4.8%カナダ: 引用元論文 654 件、この内訳の 4.7%オーストラリア: 引用元論文 620 件、この内訳の 4.5%オランダ: 引用元論文 512 件、この内訳の 3.7%フランス: 引用元論文 474 件、この内訳の 3.4%スペイン: 引用元論文 406 件、この内訳の 2.9%スイス: 引用元論文 397 件、この内訳の 2.9%ベルギー: 引用元論文 359 件、この内訳の 2.6%
0%21.8%その他 26.5%

分野

  • Medicine61.1%
  • Biochemistry, Genetics and Molecular Biology21.3%
  • Health Professions9.9%
  • Psychology1.3%
  • Social Sciences1%
  • Computer Science1%
  • その他4.4%

トピック

  • Cancer survivorship and care6.3%
  • Breast Cancer Treatment Studies5.9%
  • Patient-Provider Communication in Healthcare3.8%
  • Advanced Breast Cancer Therapies3.5%
  • Ovarian cancer diagnosis and treatment2.7%
  • HER2/EGFR in Cancer Research2.5%
  • その他75.3%

共著者

全論文

検索で開く
  1. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Silvia P. Neciosup, B.V. Offersen, Shinji Ohno, Olivia Pagani, A. Prat, Frédérique Penault‐Llorca, Hope S. Rugo, G. W. Sledge, Christoph Thomssen, D.A. Vorobiof, Theresa Wiseman, Binghe Xu, Larry Norton, A. Costa, Eric P. Winer - Annals of Oncology 2020 被引用: 1,356

  2. Ovarian Cancer Population Screening and Mortality After Long-Term Follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): A Randomised Controlled Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Obstetrical & Gynecological Survey 2021 被引用: 700

  3. 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Efthymios Papadopoulos, Fedro A. Peccatori, Frédérique Penault‐Llorca, Martine Piccart, Jean‐Yves Pierga, Hope S. Rugo, Lillie D. Shockney, George W. Sledge, Sandra M. Swain, Christoph Thomssen, Andrew Tutt, Daniel Vorobiof, Binghe Xu, Larry Norton, Eric P. Winer - Annals of Oncology 2016 被引用: 2,062

  4. Ovarian cancer

    著者: , , , , , - Nature Reviews Disease Primers 2016 被引用: 1,291

  5. The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline

    著者: , , , , , , , , , , , , , , , - Annals of Oncology 2022 被引用: 480

  6. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Dustin J. Rabideau, Karina Reynolds, Ian Scott, Mourad W. Seif, Aarti Sharma, Naveena Singh, Julie Taylor, Fiona Warburton, Martin Widschwendter, Karin Williamson, Robert Woolas, Lesley Fallowfield, Alistair McGuire, Stuart Campbell, Mahesh Parmar, Steven J. Skates - The Lancet 2015 被引用: 1,102

  7. 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Olivia Pagani, Shani Paluch–Shimon, Frédérique Penault‐Llorca, Aleix Prat, H.S. Rugo, G. W. Sledge, Danielle Spence, Christoph Thomssen, D.A. Vorobiof, B. Xu, Larry Norton, E.P. Winer - Annals of Oncology 2018 被引用: 1,190

  8. Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline

    著者: , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2016 被引用: 645

  9. Digital Health for Optimal Supportive Care in Oncology: Benefits, Limits, and Future Perspectives

    著者: , , , , , , , , , - Kompass Nutrition & Dietetics 2020 被引用: 326

  10. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Belinda E. Kiely, Sungbae Kim, Smruti Koppikar, Marion Kuper‐Hommel, Frédéric Lecouvet, Ginny Mason, Shirley Mertz, Volkmar Müller, Claire Myerson, Silvia P. Neciosup, Birgitte Vrou Offersen, Shinji Ohno, Olivia Pagani, Ann H. Partridge, Frédérique Penault‐Llorca, Aleix Prat, Hope S. Rugo, Elżbieta Senkus, George W. Sledge, Sandra M. Swain, Christoph Thomssen, Daniel Vorobiof, Peter Vuylsteke, Theresa Wiseman, Binghe Xu, Alberto Costa, Larry Norton, Eric P. Winer - The Breast 2024 被引用: 197

  11. Randomized Multicenter Trial of Sentinel Node Biopsy Versus Standard Axillary Treatment in Operable Breast Cancer: The ALMANAC Trial

    著者: , , , , , , , , , , , , , , , , , , - JNCI Journal of the National Cancer Institute 2006 被引用: 1,675

  12. Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review

    著者: , , , - Patient 2014 被引用: 160

  13. Addressing overtreatment of screen detected DCIS; the LORIS trial

    著者: , , , , , , , , , , , , , , , , , , , , , - European Journal of Cancer 2015 被引用: 375

  14. Endocrine and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer—Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Praveen Vikas, Rachel L. Yung, Hope S. Rugo - Journal of Clinical Oncology 2024 被引用: 48

  15. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study

    著者: , , , , , , , , , , , , - The Lancet Oncology 2013 被引用: 226

  16. Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Fadi Rafic El Karak, Fadi Farhat, Servando C. Huerta, Brizio M. Jaime, Juan P. Feregrino, O. Castillo, Juan Carlos Alcedo, Leonor Ribeiro, Maria Rita Dionísio, Susana Sousa, Catarina Pulido, Salha Bujassoum, Hatoon Bakhraibah, Ana Cvetanović, Ljiljana Stamatović, Álvaro Rodríguez Lescure, Josefina Cruz, Camilla Wendt, Sara Margolin, Helena Granstam Björneklett, Michelina Cairo, Shaker R. Dakhil, Nguyet Le‐Lindqwister, Ling Ma, Kristi McIntyre, Joyce O’Shaughnessy, Svetislava J. Vukelja, Donald Richards, Sharon Wilks, John M. Wallmark - European Journal of Cancer 2021 被引用: 74

  17. Comparison of psychological aspects and patient satisfaction following breast conserving surgery, simple mastectomy and breast reconstruction

    著者: , , - European Journal of Cancer 2000 被引用: 653

  18. Multidisciplinary teams in cancer care: are they effective in the UK?

    著者: , , , - The Lancet Oncology 2006 被引用: 617

  19. Tumour stage, treatment, and survival of women with high-grade serous tubo-ovarian cancer in UKCTOCS: an exploratory analysis of a randomised controlled trial

    著者: , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2023 被引用: 57

  20. A digital pathway for genetic testing in UK NHS patients with cancer: BRCA-DIRECT randomised study internal pilot

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Medical Genetics 2022 被引用: 30

  21. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ian Jacobs - The Lancet Oncology 2009 被引用: 834

  22. Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Karina Reynolds, Alistair McGuire, Stuart Campbell, Mahesh Parmar, Steven J. Skates, Ian Jacobs - Journal of Clinical Oncology 2015 被引用: 198

  23. Pulmonary Metastasectomy versus Continued Active Monitoring in Colorectal Cancer (PulMiCC): a multicentre randomised clinical trial

    著者: , , , , , , , , , - Trials 2019 被引用: 216

  24. Ovarian cancer symptoms, routes to diagnosis and survival – Population cohort study in the ‘no screen’ arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)

    著者: , , , , , , , , , , , , , , , , , , - Gynecologic Oncology 2020 被引用: 76